Dabrafenib,Trametinib
Novartis
['trametinib', 'dabrafenib']
 promising efficacy and safety of dabrafenib (braf inhibitor) &amp; trametinib (mek inhibitor) combo for patients with brafv600e-mutated advanced rare cancers. high overall response rates and manageable side effects suggest a potential treatment approach. #precisionmedicine 
On the road! Pursuing to improve global health through sharing knowledge, cancer prevention, and care. Professor, Medical oncologist @AnkaraUni